Riverwater Partners LLC Has $1.40 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Riverwater Partners LLC increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 28.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,368 shares of the medical equipment provider's stock after acquiring an additional 3,186 shares during the period. Riverwater Partners LLC's holdings in Lantheus were worth $1,402,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of LNTH. Janus Henderson Group PLC lifted its position in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock valued at $554,583,000 after acquiring an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC grew its stake in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after buying an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after purchasing an additional 30,891 shares during the period. Finally, Silvercrest Asset Management Group LLC boosted its holdings in Lantheus by 39.1% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock valued at $87,124,000 after purchasing an additional 273,838 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on LNTH shares. B. Riley cut their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a report on Monday. Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lantheus has a consensus rating of "Buy" and an average price target of $130.50.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director now owns 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.00% of the stock is currently owned by company insiders.

Lantheus Trading Up 2.0%

NASDAQ:LNTH traded up $1.62 during trading hours on Monday, hitting $80.81. The company had a trading volume of 767,678 shares, compared to its average volume of 1,014,930. The stock has a 50-day moving average price of $86.36 and a 200 day moving average price of $90.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The company has a market capitalization of $5.59 billion, a PE ratio of 22.96 and a beta of 0.11. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter in the prior year, the business posted $1.69 EPS. The business's quarterly revenue was up .8% on a year-over-year basis. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.